Elevated PSA and Obstructive LUTS

Bilal Chughtai, MD, presented “Elevated PSA and Obstructive LUTS” during the 2024 Frontiers in Oncologic Prostate Care and Ablative Local Therapy symposium on October 18, 2024, in San Diego, California.

>

How to cite: Chughtai, Bilal. “Elevated PSA and Obstructive LUTS.” October, 2024. Accessed Dec 2025. https://grandroundsinurology.com/elevated-psa-and-obstructive-luts/

Elevated PSA and Obstructive LUTS – Summary

Bilal Chughtai, MD, addresses the relationship between elevated PSA levels and obstructive LUTS, emphasizing the importance of PSA beyond its role in prostate cancer detection. In this 11-minute presentation, Dr. Chughtai explains that PSA, secreted primarily by the prostate, serves as a valuable marker for understanding BPH progression and guiding clinical decisions.

Dr. Chughtai highlights that patients with higher baseline PSA levels are more likely to experience faster prostate growth, increased symptom deterioration, and a higher risk of acute urinary retention. Furthermore, he examines the potential of PSA density to differentiate between glandular and stromal prostate tissue, aiding in selecting appropriate treatments like enucleation or ablation techniques.

Dr. Chughtai underscores the utility of PSA in managing BPH, offering clinicians a robust tool for tailoring patient care, optimizing treatment strategies, and enhancing postoperative outcomes.

Frontiers in Oncologic Prostate Care and Ablative Local Therapy (FOCAL) is an outstanding program on prostate imaging, transperineal interventions, and ablative treatments for prostate cancer and benign prostatic hyperplasia. Bringing together community-based, academic, and industry partners, FOCAL offers lectures by world-renowned faculty and hands-on training workshops on in-office transperineal interventions, fusion-guided prostate ablation and state-of-the-art BPH management with novel technologies.